1-5 of 5
L. Rhoda Molife
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Saeed Rafii, Desamparados Roda, Elena Geuna, Begona Jimenez, Karim Rihawi, Marta Capelan, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1869–1876.
https://doi.org/10.1158/1078-0432.CCR-14-2424
Published: 14 April 2015
View article titled, Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials
Open the PDF for Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials in another window
Includes: Supplementary data
Journal Articles

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

L. Rhoda Molife, Emma Jane Dean, Montserrat Blanco-Codesido, Matthew G. Krebs, Andre T. Brunetto, Alastair Peter Greystoke, Gennaro Daniele, Lucy Lee, Galina Kuznetsov, Khin Than Myint, Karen Wood, Begoña de las Heras, Malcolm Richard Ranson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6284–6294.
https://doi.org/10.1158/1078-0432.CCR-14-0409
Published: 14 December 2014
View article titled, A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors in another window
Journal Articles

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

André T. Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L. Rhoda Molife, Rebecca Kristeleit, Ann Parker, Isabel Casamayor, Muyibat Olaleye, Anna Mais, Bernhard Hauns, Vera Strobel, Bernd Hentsch, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5494–5504.
https://doi.org/10.1158/1078-0432.CCR-13-0735
Published: 01 October 2013
View article titled, First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience

Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (14): 3750–3761.
https://doi.org/10.1158/1078-0432.CCR-11-1275
Published: 15 July 2012
View article titled, Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Open the PDF for Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience in another window
Journal Articles

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Paul Haluska, Heather M. Shaw, Gretchen N. Batzel, Donghua Yin, Julian R. Molina, L. Rhoda Molife, Timothy A. Yap, M. Luisa Roberts, Amarnath Sharma, Antonio Gualberto, Alex A. Adjei, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5834–5840.
https://doi.org/10.1158/1078-0432.CCR-07-1118
Published: 01 October 2007
View article titled, Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors
Open the PDF for Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors in another window